MA31594B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA31594B1 MA31594B1 MA32591A MA32591A MA31594B1 MA 31594 B1 MA31594 B1 MA 31594B1 MA 32591 A MA32591 A MA 32591A MA 32591 A MA32591 A MA 32591A MA 31594 B1 MA31594 B1 MA 31594B1
- Authority
- MA
- Morocco
- Prior art keywords
- organic compounds
- compounds
- phosphosyllol
- solvates
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU UN SEL, ET, DE MANIÈRE APPROPRIÉE, L'UN DE SES SELS ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE OU DES SOLVATES, OÙ LES GROUPES R1, R2, AR', A ET B SONT DÉFINIS DANS LA DESCRIPTION. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS ET L'UTILISATION DES COMPOSÉS DANS LE TRAITEMENT DE MALADIES AMÉLIORÉES PAR L'INHIBITION DE LA PHOSPHATIDYLINOSITOL-3-KINASE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113237 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31594B1 true MA31594B1 (fr) | 2010-08-02 |
Family
ID=38942282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32591A MA31594B1 (fr) | 2007-07-26 | 2010-02-05 | Composes organiques |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2173722B1 (fr) |
JP (1) | JP5485884B2 (fr) |
KR (1) | KR20100025006A (fr) |
CN (1) | CN101765591B (fr) |
AR (1) | AR067869A1 (fr) |
AU (1) | AU2008278966B2 (fr) |
BR (1) | BRPI0813629A2 (fr) |
CA (1) | CA2694275A1 (fr) |
CL (1) | CL2008002185A1 (fr) |
CO (1) | CO6290670A2 (fr) |
CR (1) | CR11208A (fr) |
EA (1) | EA201000104A1 (fr) |
EC (1) | ECSP109900A (fr) |
ES (1) | ES2394126T3 (fr) |
MA (1) | MA31594B1 (fr) |
MX (1) | MX2010001020A (fr) |
PE (1) | PE20090880A1 (fr) |
SV (1) | SV2010003464A (fr) |
TN (1) | TN2010000038A1 (fr) |
TW (1) | TW200909426A (fr) |
WO (1) | WO2009013348A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
CA2755285C (fr) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibiteurs de pi3 kinase |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
JP4967004B2 (ja) * | 2009-09-14 | 2012-07-04 | 東京エレクトロン株式会社 | レジスト塗布現像装置およびレジスト塗布現像方法 |
EA032458B1 (ru) | 2014-01-14 | 2019-05-31 | Милленниум Фармасьютикалз, Инк. | Гетероарилы и их применение |
WO2015108881A1 (fr) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
US10004732B2 (en) | 2014-04-24 | 2018-06-26 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
AU2014391610B2 (en) * | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
CA3085460A1 (fr) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Derives d'amine aryl-bipyridine utilises en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase |
EP3762368B1 (fr) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
AU2002310187A1 (en) * | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
AUPR688101A0 (en) * | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
WO2003030909A1 (fr) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
TWI330183B (fr) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
JP2006510597A (ja) * | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
CA2507100C (fr) * | 2002-11-21 | 2012-10-09 | Chiron Corporation | Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer |
SI2316831T1 (sl) * | 2002-11-21 | 2013-07-31 | Novartis Ag | 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka |
RS53118B (en) * | 2003-02-26 | 2014-06-30 | Sugen Inc. | AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
EP1641535A4 (fr) * | 2003-06-30 | 2008-05-14 | Merck & Co Inc | Derives de 17-acetamido-4-azasteroide en tant que modulateurs du recepteur d'androgene |
ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
JP2008508303A (ja) * | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20110098301A1 (en) * | 2005-03-10 | 2011-04-28 | Bayer Healthcare Llc | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders |
WO2007111904A2 (fr) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la c-met proteine kinase |
GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
GB0610242D0 (en) * | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
BRPI0714614A2 (pt) * | 2006-07-28 | 2013-05-14 | Novartis Ag | quinazolina 2,4-substituÍdas como inibidores de lipÍdeos cinase |
WO2008025821A1 (fr) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Dérivés de triazole en tant qu'inhibiteurs de kinase |
TWI444379B (zh) * | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Raf激酶抑制劑之化合物 |
-
2008
- 2008-07-24 CA CA2694275A patent/CA2694275A1/fr not_active Abandoned
- 2008-07-24 WO PCT/EP2008/059748 patent/WO2009013348A2/fr active Application Filing
- 2008-07-24 JP JP2010517408A patent/JP5485884B2/ja active Active
- 2008-07-24 BR BRPI0813629A patent/BRPI0813629A2/pt not_active IP Right Cessation
- 2008-07-24 CN CN2008801002897A patent/CN101765591B/zh active Active
- 2008-07-24 EA EA201000104A patent/EA201000104A1/ru unknown
- 2008-07-24 AU AU2008278966A patent/AU2008278966B2/en not_active Expired - Fee Related
- 2008-07-24 KR KR1020107001657A patent/KR20100025006A/ko active IP Right Grant
- 2008-07-24 ES ES08775347T patent/ES2394126T3/es active Active
- 2008-07-24 EP EP08775347A patent/EP2173722B1/fr active Active
- 2008-07-24 PE PE2008001259A patent/PE20090880A1/es not_active Application Discontinuation
- 2008-07-24 MX MX2010001020A patent/MX2010001020A/es not_active Application Discontinuation
- 2008-07-25 CL CL2008002185A patent/CL2008002185A1/es unknown
- 2008-07-25 TW TW097128507A patent/TW200909426A/zh unknown
- 2008-07-28 AR ARP080103260A patent/AR067869A1/es not_active Application Discontinuation
-
2010
- 2010-01-08 CR CR11208A patent/CR11208A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000038A patent/TN2010000038A1/fr unknown
- 2010-01-25 CO CO10007032A patent/CO6290670A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003464A patent/SV2010003464A/es not_active Application Discontinuation
- 2010-01-26 EC EC2010009900A patent/ECSP109900A/es unknown
- 2010-02-05 MA MA32591A patent/MA31594B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN101765591B (zh) | 2013-11-27 |
JP2010534634A (ja) | 2010-11-11 |
CL2008002185A1 (es) | 2009-02-20 |
WO2009013348A3 (fr) | 2009-07-23 |
AU2008278966A1 (en) | 2009-01-29 |
CA2694275A1 (fr) | 2009-01-29 |
CR11208A (es) | 2010-02-12 |
EP2173722B1 (fr) | 2012-08-29 |
PE20090880A1 (es) | 2009-08-06 |
CN101765591A (zh) | 2010-06-30 |
MX2010001020A (es) | 2010-03-01 |
TW200909426A (en) | 2009-03-01 |
WO2009013348A2 (fr) | 2009-01-29 |
ES2394126T3 (es) | 2013-01-22 |
AU2008278966B2 (en) | 2012-02-23 |
ECSP109900A (es) | 2010-02-26 |
CO6290670A2 (es) | 2011-06-20 |
BRPI0813629A2 (pt) | 2018-07-10 |
EA201000104A1 (ru) | 2010-08-30 |
JP5485884B2 (ja) | 2014-05-07 |
KR20100025006A (ko) | 2010-03-08 |
AR067869A1 (es) | 2009-10-28 |
TN2010000038A1 (en) | 2011-09-26 |
SV2010003464A (es) | 2010-05-21 |
EP2173722A2 (fr) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31594B1 (fr) | Composes organiques | |
MA54327B1 (fr) | Inhibiteurs de kras g12c | |
MA33734B1 (fr) | N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase | |
HRP20040686B1 (hr) | Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza | |
MA32231B1 (fr) | Composés organiques | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
EA200802329A1 (ru) | Производные триазола ii | |
NO20030896D0 (no) | Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler | |
MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
MA31419B1 (fr) | Derives de pyridine | |
NO20061194L (no) | Mitotiske kinesininbibitorer | |
NZ579296A (en) | Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections | |
MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
MA30412B1 (fr) | Composés Pharmaceutiques | |
PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
ECSP055729A (es) | Nuevos inhibidores biciclicos de la lipasa sensible a hormonas | |
BRPI0511111A (pt) | compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários | |
MA39043A1 (fr) | Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs | |
BR0317183A (pt) | Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno | |
CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
SE0301232D0 (sv) | Novel use |